This is a drug-drug interaction study for TGRX-326 to evaluate the effects of CYP3A inhibitor/inducer drugs on pharmacokinetic profiles of TGRX-326, an ALK inhibitor indicated for treatment of Non-small cell lung cancer.
Phase:
PHASE1
Details
Lead Sponsor:
Shenzhen TargetRx, Inc.
Collaborator:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School